Drug intelligence / Profile preview

Jiexingjunzi granule

Development stage: Unknown
Lead developer: Hongsheng Cui
Administration: Oral

Overview

Jiexingjunzi granule is a traditional Chinese medicine (TCM) formulation developed for the treatment of convalescent patients recovering from novel coronavirus pneumonia (COVID-19). It is administered as a herbal granule and has been studied in clinical trials to assess its efficacy and safety in improving recovery outcomes for COVID-19 patients. The precise composition of the herbal ingredients and detailed mechanism of action are not specified in available sources. The product is used within the framework of TCM principles, likely aiming to restore balance and support immune function during post-infection recovery[1][2][8].

Brand names: Jiexingjunzi granuleJie-Xing-Jun-Zi granules
Other names: JiexingjunziJie-Xing-Jun-Zi

Beyond the preview

Go deeper on Jiexingjunzi granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiexingjunzi granule.

Explore the full profile